Gynäkologische Endokrinologie

, Volume 5, Issue 4, pp 223–234 | Cite as

Niedrig dosierte Gonadotropinstimulation in der gynäkologischen Praxis

CME Weiterbildung • Zertifizierte Fortbildung


Die niedrig dosierte Gonadotropinstimulation mit humanem Menopausengonadotropin (HMG) oder rekombinantem humanem FSH (r-hFSH) kann bei anovulatorischen Zyklen, unregelmäßigen Zyklen oder zur Optimierung der Konzeptionschancen bei einer Lutealphaseninsuffizienz eingesetzt werden. Die Gonadotropindosis muss der individuellen Situation der Patientin angepasst werden, um das Mehrlingsrisiko zu minimieren. Patientinnen mit einem PCO-Syndrom erfordern einen besonderen Therapieansatz, um einer multifollikulären Reifung entgegenzuwirken (Step-up- oder Step-down-Protokoll).


FSH PCO-Syndrom Step-up-Protokoll Step-down-Protokoll Gonadotropinstimulation 

Low-dose gonadotropin stimulation in gynecological practice


Low-dose gonadotropin stimulation with either human menopausal gonadotropin (HMG) or recombinant human FSH (rhFSH) is used for anovulatory infertility and irregular cycles or for optimization in cases of luteal phase insufficiency. The gonadotropin dose must be adjusted to the individual patient’s situation, especially to minimize the risk of a multiple pregnancy. A special approach has to be chosen in the case of PCO syndrome patients. The step-down or step-up protocol is helpful in these situations.


FSH PCO syndrome Step-up protocol Step-down protocol Gonadotropin stimulation 



Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.


  1. 1.
    The European Recombinant Human LH Study Group (1998) Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab 83(5): 1507–1514CrossRefGoogle Scholar
  2. 2.
    Andoh K, Mizunuma H, Liu X et a l. (1998) A comparative study of fixed-dose, step-down, and low-dose step-up regimens of human menopausal gonadotropin for patients with polycystic ovary syndrome. Fertil Steril 70(5): 840–846PubMedCrossRefGoogle Scholar
  3. 3.
    Balasch J, Fabregues F, Creus M et al. (2001) Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens. Hum Reprod 16(4): 652–656PubMedCrossRefGoogle Scholar
  4. 4.
    Balasch J, Miro F, Burzaco I et al. (1995) The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone. Hum Reprod 10(7): 1678–1683PubMedGoogle Scholar
  5. 5.
    Christin-Maitre S, Hugues JN (2003) A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum Reprod 18(8): 1626–1631PubMedCrossRefGoogle Scholar
  6. 6.
    De Geyter C, De Geyter M, Castro E et al. (1996) Experience with transvaginal ultrasound-guided aspiration of supernumerary follicles for the prevention of multiple pregnancies after ovulation induction and intrauterine insemination. Fertil Steril 65(6): 1163–1168Google Scholar
  7. 7.
    de Vet A, Laven JS, de Jong FH et al. (2002) Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 77(2): 357–362CrossRefGoogle Scholar
  8. 8.
    Dunson DB, Baird DD, Wilcox AJ, Weinberg CR (1999) Day-specific probabilities of clinical pregnancy based on two studies with imperfect measures of ovulation. Hum Reprod 14(7): 1835–1839PubMedCrossRefGoogle Scholar
  9. 9.
    Fanchin R, Righini C, Olivennes F et al. (1999) Computerized assessment of endometrial echogenicity: clues to the endometrial effects of premature progesterone elevation. Fertil Steril 71(1): 174–181PubMedCrossRefGoogle Scholar
  10. 10.
    Filicori M, Cognigni GE, Tabarelli C et al. (2002) Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. J Clin Endocrinol Metab 87(3): 1156–1161PubMedCrossRefGoogle Scholar
  11. 11.
    Gill S, Taylor AE, Martin KA et al. (2001) Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome. J Clin Endocrinol Metab 86(6): 2428–2436PubMedCrossRefGoogle Scholar
  12. 12.
    Gleicher N, Oleske DM, Tur-Kaspa I et al. (2000) Reducing the risk of high-order multiple pregnancy after ovarian stimulation with gonadotropins. N Engl J Med 343(1): 2–7PubMedCrossRefGoogle Scholar
  13. 13.
    Gougeon A (1986) Dynamics of follicular growth in the human: a model from preliminary results. Hum Reprod 1(2): 81–87PubMedGoogle Scholar
  14. 14.
    Goverde AJ, McDonnell J, Vermeiden JP et al. (2000) Intrauterine insemination or in-vitro fertilisation in idiopathic subfertility and male subfertility: a randomised trial and cost-effectiveness analysis. Lancet 1(355): 13–18CrossRefGoogle Scholar
  15. 15.
    Hehenkamp WJ, Looman CW, Themmen AP et al. (2006) Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab 91(10): 4057–4063PubMedCrossRefGoogle Scholar
  16. 16.
    Hillier SG (2001) Gonadotropic control of ovarian follicular growth and development. Mol Cell Endocrinol 20(179): 39–46CrossRefGoogle Scholar
  17. 17.
    Hugues JN, Cedrin-Durnerin I, Avril C et al. (1996) Sequential step-up and step-down dose regimen: an alternative method for ovulation induction with follicle-stimulating hormone in polycystic ovarian syndrome. Hum Reprod 11(12): 2581–2584PubMedGoogle Scholar
  18. 18.
    Hugues JN, Soussis J, Calderon I et al. (2005) Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study. Hum Reprod 20(3): 629–635PubMedCrossRefGoogle Scholar
  19. 19.
    Imani B, Eijkemans MJ, Faessen GH et al. (2002) Prediction of the individual follicle-stimulating hormone threshold for gonadotropin induction of ovulation in normogonadotropic anovulatory infertility: an approach to increase safety and efficiency. Fertil Steril 77(1): 83–90PubMedCrossRefGoogle Scholar
  20. 20.
    Keck C, Bassett R, Ludwig M (2005) Factors influencing response to ovarian stimulation. Reprod Biomed Online 11(5): 562–569PubMedCrossRefGoogle Scholar
  21. 21.
    Kevenaar ME, Meerasahib MF, Kramer P et al. (2006) Serum anti-mullerian hormone levels reflect the size of the primordial follicle pool in mice. Endocrinology 147(7): 3228–3234PubMedCrossRefGoogle Scholar
  22. 22.
    La MA, Giulini S, Tirelli A et al. (2007) Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 22(3): 766–771Google Scholar
  23. 23.
    La MA, Stabile G, Artenisio AC, Volpe A (2006) Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod 21(12): 3103–3107CrossRefGoogle Scholar
  24. 24.
    Laven JS, Mulders AG, Visser JA et al. (2004) Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 89(1): 318–323PubMedCrossRefGoogle Scholar
  25. 25.
    Ludwig M (2006) Ovar. In: Siegenthaler W, Blum HE (Hrsg) Klinische Pathophysiologie, 9. Aufl. Thieme, Stuttgart New York, S 368–405Google Scholar
  26. 26.
    Ludwig M, Doody KJ, Doody KM (2003) Use of recombinant human chorionic gonadotropin in ovulation induction. Fertil Steril 79(5): 1051–1059PubMedCrossRefGoogle Scholar
  27. 27.
    McArdle CR, Seibel M, Weinstein F et al. (1983) Induction of ovulation monitored by ultrasound. Radiology 148(3): 809–812PubMedGoogle Scholar
  28. 28.
    Meduri G, Massin N, Guibourdenche J et al. (2007) Serum anti-Mullerian hormone expression in women with premature ovarian failure. Hum Reprod 22(1): 117–123PubMedCrossRefGoogle Scholar
  29. 29.
    Nawroth F (2007) Anwendung von Clomifen zur ovariellen Stimulation. Gynäkol Endokrinol 1: 39–47CrossRefGoogle Scholar
  30. 30.
    Oktay K, Newton H, Mullan J, Gosden RG (1998) Development of human primordial follicles to antral stages in SCID/hpg mice stimulated with follicle stimulating hormone. Hum Reprod 13(5): 1133–1138PubMedCrossRefGoogle Scholar
  31. 31.
    Prietl G, Haidl G, Krebs D (2000) Sterilitätsbehandlung durch homologe intrauterine Insemination. Reproduktionsmedizin 16: 376–383CrossRefGoogle Scholar
  32. 32.
    Richmond JR, Deshpande N, Lyall H et al. (2005) Follicular diameters in conception cycles with and without multiple pregnancy after stimulated ovulation induction. Hum Reprod 20(3): 756–760PubMedCrossRefGoogle Scholar
  33. 33.
    Richter KS, Bugge KR, Bromer JG, Levy MJ (2007) Relationship between endometrial thickness and embryo implantation, based on 1,294 cycles of in vitro fertilization with transfer of two blastocyst-stage embryos. Fertil Steril 87(1): 53–59PubMedCrossRefGoogle Scholar
  34. 34.
    Robinson JE, Wakelin M, Ellis JE (2007) Increased pregnancy rate with use of the Clearblue Easy Fertility Monitor. Fertil Steril 87(2): 329–334PubMedCrossRefGoogle Scholar
  35. 35.
    Tsepelidis S, Devreker F, Demeestere I et al. (2007) Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum Reprod 17 (in press)Google Scholar
  36. 36.
    van Santbrink EJ, Fauser BC (1997) Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: prospective, randomized comparison between low dose step-up and step-down dose regimens. J Clin Endocrinol Metab 82(11): 3597–3602CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2007

Authors and Affiliations

  1. 1.Zentrum für Hormon- und Stoffwechselerkrankungen, Reproduktionsmedizin und Gynäkologische EndokrinologieEndokrinologikum HamburgHamburgDeutschland

Personalised recommendations